Tranilast as an adjunctive therapy in hospitalized patients with severe COVID-19: a randomized controlled trial

A Saeedi-Boroujeni, R Nashibi, AA Ghadiri… - Archives of medical …, 2022 - Elsevier
Background Tranilast is a potential NLRP3 inflammasome inhibitor that may relieve
progressive inflammation due to COVID-19. Aim of the study To evaluate the therapeutic …
被引用次数：18 相关文章
[HTML] nih.gov

[HTML][HTML] Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID-19: A Randomized Controlled Trial

A Saeedi-Boroujeni, R Nashibi, AA Ghadiri… - Archives of Medical …, 2022 - ncbi.nlm.nih.gov
Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A
Randomized Controlled Trial - PMC Back to Top Skip to main content NIH NLM Logo Access …
[PDF] researchgate.net

[PDF][PDF] Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID-19: A Randomized Controlled Trial

A Saeedi-Boroujeni, R Nashibi, AA Ghadiri… - researchgate.net
Background. Tranilast is a potential NLRP3 inflammasome inhibitor that may relieve
progressive inflammation due to COVID-19. Aim of the study. To evaluate the therapeutic …

Tranilast as an adjunctive therapy in hospitalized patients with severe COVID-19: a randomized controlled trial.

A Saeedi-Boroujeni, R Nashibi, AA Ghadiri… - 2022 - cabidigitallibrary.org
Background: Tranilast is a potential NLRP3 inflammasome inhibitor that may relieve
progressive inflammation due to COVID-19. Aim of the study: To evaluate the therapeutic …

Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID-19: A Randomized Controlled Trial

A Saeedi-Boroujeni, R Nashibi, AA Ghadiri… - 2022 - pubmed.ncbi.nlm.nih.gov
Background Tranilast is a potential NLRP3 inflammasome inhibitor that may relieve
progressive inflammation due to COVID-19. Aim of the study To evaluate the therapeutic …
[PDF] academia.edu

[PDF][PDF] Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID-19: A Randomized Controlled Trial

A Saeedi-Boroujeni, R Nashibi, AA Ghadiri… - Archives of Medical …, 2022 - academia.edu
Background. Tranilast is a potential NLRP3 inflammasome inhibitor that may relieve
progressive inflammation due to COVID-19. Aim of the study. To evaluate the therapeutic …

Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID-19: A Randomized Controlled Trial.

A Saeedi-Boroujeni, R Nashibi, AA Ghadiri… - Archives of Medical …, 2022 - europepmc.org
Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A
Randomized Controlled Trial. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …